Glaukos (GKOS) to Announce Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) is expected to release its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Glaukos to announce earnings of ($0.2235) per share and revenue of $150.9940 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. The business’s quarterly revenue was up 41.2% compared to the same quarter last year. On average, analysts expect Glaukos to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Glaukos Trading Down 1.0%

Shares of Glaukos stock opened at $152.07 on Tuesday. The firm has a market cap of $8.93 billion, a price-to-earnings ratio of -46.36 and a beta of 0.75. Glaukos has a 52-week low of $73.16 and a 52-week high of $161.53. The company’s 50-day simple moving average is $136.04 and its 200-day simple moving average is $123.80. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 19,573 shares of Glaukos stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the transaction, the chief operating officer directly owned 73,419 shares of the company’s stock, valued at approximately $10,538,563.26. The trade was a 21.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Leana Wen sold 1,700 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.35, for a total value of $243,695.00. Following the sale, the director owned 19,739 shares in the company, valued at approximately $2,829,585.65. The trade was a 7.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 61,273 shares of company stock valued at $8,882,003. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Glaukos

A number of large investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC acquired a new position in Glaukos during the fourth quarter worth about $209,000. Invesco Ltd. lifted its holdings in shares of Glaukos by 28.5% in the fourth quarter. Invesco Ltd. now owns 780,267 shares of the medical instruments supplier’s stock valued at $88,100,000 after purchasing an additional 172,825 shares in the last quarter. Corient Private Wealth LLC grew its position in shares of Glaukos by 999.3% in the fourth quarter. Corient Private Wealth LLC now owns 30,978 shares of the medical instruments supplier’s stock valued at $3,498,000 after purchasing an additional 28,160 shares during the last quarter. Summit Global Investments grew its position in shares of Glaukos by 151.3% in the fourth quarter. Summit Global Investments now owns 7,052 shares of the medical instruments supplier’s stock valued at $796,000 after purchasing an additional 4,246 shares during the last quarter. Finally, Mackenzie Financial Corp increased its stake in shares of Glaukos by 331.8% during the 4th quarter. Mackenzie Financial Corp now owns 15,404 shares of the medical instruments supplier’s stock worth $1,756,000 after purchasing an additional 11,837 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GKOS shares. Citigroup lifted their price objective on Glaukos from $162.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. William Blair reissued an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. Wells Fargo & Company lifted their price target on Glaukos from $135.00 to $138.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Stifel Nicolaus upped their price objective on Glaukos from $170.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $154.85.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.